【Can-Fite BioPharma- Product CF101】Can-Fite’s Phase III Psoriasis Study To Complete 16-Week Treatment Of Last Patient In January; Topline Data Expected Q1 2022
Can-Fite announced the last of approximately 400 psoriasis patients enrolled in its Phase III Comfort? study is scheduled to complete a 16-week cycle of treatment with Piclidenoson, at the beginning of January 2022. The 16-week treatment period is the primary endpoint of the study, and the Company expects to announce topline results during Q1 2022.
The randomized, double blind, active and placebo controlled study is being conducted in Europe, Israel, and Canada. The study’s primary endpoint is the proportion of patients who achieve a PASI score response of ≥75% (PASI 75) vs. placebo at week 16. Secondary endpoints include non-inferiority to Otezla® in weeks 16 and 32. “Completion of treatment in a Phase III study is a significant milestone for our lead drug candidate. We were encouraged by the positive interim data analysis provided by the Independent Data Monitoring Committee following treatment of the first 200 patients in this study.” stated Can-Fite CEO Dr. Pnina Fishman.
Otezla reported generating $2.2 billion in sales in 2020. According to iHealthcareAnalyst, the psoriasis therapeutic market is estimated to reach $11.3 billion by 2025.